HIV vaccine development at Duke University Medical Center.
With the AIDS epidemic continuing to spread throughout the world, development of a safe, practical, and effective HIV vaccine is a national priority. HIV vaccine research efforts are currently targeted towards design of HIV immunogens that induce both cellular and humoral immunity. This brief review summarizes ongoing work at the Duke University School of Medicine on HIV vaccine development.
Haynes
B F
BF
Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA. hayne002@mc.duke.edu
Liao
H X
HX
Staats
H F
HF
Alam
M S
MS
Weinhold
K J
KJ
Montefiori
D C
DC
D016915:AIDS Vaccines; D000046:Academic Medical Centers; D000276:Adjuvants, Immunologic; D000595:Amino Acid Sequence; D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology; D000939:Epitopes / Q000235:genetics; D015699:HIV Envelope Protein gp120 / Q000235:genetics; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D008969:Molecular Sequence Data; D009657:North Carolina; D010446:Peptide Fragments / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D016207:Cytokines; D000939:Epitopes; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D006680:HLA Antigens; D010446:Peptide Fragments; D014614:Vaccines, Synthetic